MSF reveals cost of its landmark TB clinical trial: €34 million
April 26, 2024MSF urges public and non-profit actors to publish clinical trial costs to improve access to medical products for all. Geneva, 25 April 2024 - At the 5th WHO Pharmaceutical Pricing and Reimbursement Policies conference today, Doctors Without Borders/Médecins Sans Frontières...
Read moreMyanmar: I have defeated TB and I wish the same for other patients
April 8, 2024Multi-drug resistant tuberculosis is one of the most complex types of tuberculosis you can get. As opposed to drug-sensitive, which responds well to the medication, multi-drug resistant tuberculosis, by its very name, is resistant to some of the drugs used...
Read morePatient Stories: Ensuring recovery through timely, accurate drug-resistant tuberculosis testing
March 18, 2024Ahmad, 11, from Tatlay Aali, a town in Gujranwala district, Pakistan, was diagnosed with tuberculosis (TB) when he was just five years old. "We’d never heard about this disease, nobody from our family ever had it. At the same time,...
Read moreMSF: TB test price reduction by Cepheid and Danaher is an important step in the right direction
September 19, 2023Cepheid and its parent company Danaher announced today that they are reducing the price of the Xpert MTB/RIF test for TB by 20 percent in high-TB-burden countries from US$9.98 to $7.97 per test. This reduction is a significant step, considering the...
Read moreAhead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need
September 12, 2023TB is curable but remains the world’s leading infectious disease killer 12 September 2023, Geneva/New York – Next week, world leaders meet for the second-ever global tuberculosis (TB) High-Level Meeting at the United Nations (UN) in New York, to endorse...
Read moreMSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics
July 18, 2023MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India today, opening door to more affordable generics. Recent deal offering controlled generics access in limited countries does not go...
Read moreMSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug
March 23, 2023Mumbai, 23 March 2023 – Today, the 2019 patent challenge by two tuberculosis (TB) survivors, Nandita Venkatesan and Phumeza Tisile, was successful: the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly...
Read moreUrgent need to improve access to TB testing to support rollout of better, safer, shorter treatment for drug-resistant TB
March 22, 2023Delhi, 22 March 2023 - Médecins Sans Frontières/Doctors Without Borders (MSF) called on governments and donors today to speed up access to new, shorter, safer and more effective treatments* for drug-resistant tuberculosis (DR-TB), as well as the diagnostic tests needed...
Read moreAfghanistan: The MSF hospital in Kandahar provides hope for people with TB
December 8, 2022Jawahira was referred to the Médecins Sans Frontières (MSF) tuberculosis (TB) hospital in Kandahar earlier this year from a clinic in Daikundi, central Afghanistan. “I used to visit private clinics, but instead of giving me TB medication, they usually just...
Read moreBetween life and living: Patients with drug-resistant tuberculosis (DR-TB) share stories of strength, support and suffering
December 2, 2022India has the highest burden of both tuberculosis (TB) and multi-drug resistant tuberculosis (MDR-TB) based on estimates in the WHO Global TB Report 2022. The country accounts for 28 percent of the global TB burden. In its clinic in Mumbai, MSF...
Read moreGlobal TB Report 2022: MSF calls for scale up of shorter and safer DR-TB treatments to help save more lives
October 28, 2022The World Health Organization (WHO) released today the 2022 edition of its Global Tuberculosis (TB) Report, featuring data on the TB response and trends in 215 countries and areas. Among the alarming trends from 2021, there is an increase in the estimated...
Read moreTuberculosis: EndTB clinical trial for multidrug-resistant TB completes enrolment
October 18, 2021BOSTON/PARIS — Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard medications. A group of scientists and...
Read more